{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:58:29Z","timestamp":1763017109780},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Quality and Outcomes"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Clinical practice guidelines that help clinicians and patients to understand the magnitude of expected individual risks and benefits would help with patient-centered decision-making and prioritization of care. We assessed the net benefit from taking daily aspirin to estimate the individual and public health implications of a more individualized decision-making approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>We used data from the National Health and Nutrition Examination Survey representing all US persons aged 30 to 85 years with no history of myocardial infarction and applied a Markov model based on randomized evidence and published literature to estimate lifetime effects of aspirin treatment in quality-adjusted life years (QALYs). We found that treatment benefit varies greatly by an individual's cardiovascular disease (CVD) risk. Almost all adults have fewer major clinical events on aspirin, but for most, events prevented would be so rare that even a very small distaste for aspirin use would make treatment inappropriate. With minimal dislike of aspirin use (disutility, 0.005 QALY per year), only those with a 10-year cardiac event risk &gt;6.1% would have a net benefit. A disutility of 0.01 QALY moves this benefit cut point to 10.6%. Multiple factors altered the absolute benefit of aspirin, but the strong relationship between CVD risk and magnitude of benefit was robust.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>The benefits of aspirin therapy depend substantially on an individual's risk of CVD and adverse treatment effects. Understanding who benefits from aspirin use and how much can help clinicians and patients to develop a more patient-centered approach to preventive therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circoutcomes.110.959239","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T03:45:58Z","timestamp":1302666358000},"page":"268-275","update-policy":"http:\/\/dx.doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Individual and Population Benefits of Daily Aspirin Therapy"],"prefix":"10.1161","volume":"4","author":[{"given":"Jeremy B.","family":"Sussman","sequence":"first","affiliation":[{"name":"From the Department of Veterans Affairs, VA Health Service Research and Development Center of Excellence, VA Ann Arbor Healthcare System (J.B.S., S.V., R.A.H.), and Department of Internal Medicine and The Robert Wood Johnson Clinical Scholars Program, University of Michigan (J.B.S., S.V., H.C., R.A.H.), Ann Arbor, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Vijan","sequence":"additional","affiliation":[{"name":"From the Department of Veterans Affairs, VA Health Service Research and Development Center of Excellence, VA Ann Arbor Healthcare System (J.B.S., S.V., R.A.H.), and Department of Internal Medicine and The Robert Wood Johnson Clinical Scholars Program, University of Michigan (J.B.S., S.V., H.C., R.A.H.), Ann Arbor, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HwaJung","family":"Choi","sequence":"additional","affiliation":[{"name":"From the Department of Veterans Affairs, VA Health Service Research and Development Center of Excellence, VA Ann Arbor Healthcare System (J.B.S., S.V., R.A.H.), and Department of Internal Medicine and The Robert Wood Johnson Clinical Scholars Program, University of Michigan (J.B.S., S.V., H.C., R.A.H.), Ann Arbor, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney A.","family":"Hayward","sequence":"additional","affiliation":[{"name":"From the Department of Veterans Affairs, VA Health Service Research and Development Center of Excellence, VA Ann Arbor Healthcare System (J.B.S., S.V., R.A.H.), and Department of Internal Medicine and The Robert Wood Johnson Clinical Scholars Program, University of Michigan (J.B.S., S.V., H.C., R.A.H.), Ann Arbor, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2466"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-2-201001190-00004"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1550"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-10-23"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-1-200807010-00005"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.3.306"},{"key":"e_1_3_4_8_2","unstructured":"Bayer HealthCare. Aspirin to reduce risk of vascular events. http:\/\/www.arrive-study.com\/EN\/aspirin-stuides-ongoing-studies.cfm. Accessed March 8 2011."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000020190.45892.75"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-6-200903170-00008"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S011"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4531"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90861-B"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.107.487090"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.15.1684"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.05.016"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90072-9"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.055145"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.6999.222"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00405-X"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/hs0901.094253"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9301300210"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9301300202"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.3.290"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-5-200603070-00007"},{"key":"e_1_3_4_27_2","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics. National Health and Nutrition Examination Survey. http:\/\/www.cdc.gov\/nchs\/nhanes.htm. Accessed December 18 2009."},{"key":"e_1_3_4_28_2","volume-title":"Microeconometrics Using Stata","author":"Cameron AC","year":"2009","unstructured":"Cameron AC, Trivedi PK. Microeconometrics Using Stata: College Station, TX: Stata Press; 2009."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0500500404"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.18.1837"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.3.312"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000080678.09344.8D"},{"key":"e_1_3_4_33_2","first-page":"2241","article-title":"Predicting the risk of gastrointestinal bleeding due to nonsteroidal antiinflammatory drugs: NSAID electronic assessment of risk","volume":"30","author":"Cheetham TC","year":"2003","unstructured":"Cheetham TC, Levy G, Spence M. Predicting the risk of gastrointestinal bleeding due to nonsteroidal antiinflammatory drugs: NSAID electronic assessment of risk. J Rheumatol. 2003;30:2241\u20132244.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_34_2","first-page":"1","article-title":"United States life tables, 2004","volume":"56","author":"Arias E","year":"2007","unstructured":"Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007;56:1\u201339.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_4_35_2","first-page":"1","article-title":"Deaths: leading causes for 2004","volume":"56","author":"Heron M","year":"2007","unstructured":"Heron M. Deaths: leading causes for 2004. Natl Vital Stat Rep. 2007;56:1\u201395.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191259"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-4-200902170-00005"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0521"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.735340"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318158af40"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00462-7"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000277983.23934.c9"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050613"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61003-5"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.10.1209"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-11-85"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3181e3b133"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510330081039"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7016.1356"}],"container-title":["Circulation: Cardiovascular Quality and Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCOUTCOMES.110.959239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:32:57Z","timestamp":1715567577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCOUTCOMES.110.959239"}},"subtitle":["A Proposal for Personalizing National Guidelines"],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1161\/CIRCOUTCOMES.110.959239"],"URL":"https:\/\/doi.org\/10.1161\/circoutcomes.110.959239","relation":{},"ISSN":["1941-7713","1941-7705"],"issn-type":[{"value":"1941-7713","type":"print"},{"value":"1941-7705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"2010-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}